SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced the completion of a private placement of $50 million, bringing the total raised to $259 million since the company’s founding in 2013.
“We have used our proprietary DNA synthesis platform, which delivers precision at a scale previously not available, to develop a portfolio of diverse products for two large market opportunities – the synthetic biology market through our gene and oligo pool offerings, and the next-generation sequencing market through our exome and custom target enrichment solutions,” said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “We plan to use a portion of these funds to invest in the emerging vertical market opportunity presented by storing digital data in DNA as well as forward integration toward drug discovery.”
About Twist Bioscience Corporation
At Twist Bioscience Corporation, we work in service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals and data storage, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. We believe that the faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.
Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.
